Merck reports positive phase 2b results for anti-TL1A antibody in hidradenitis suppurativa

Merck announced that its experimental anti-TL1A antibody achieved a positive outcome in a phase 2b study.

The trial enrolled patients with moderate to severe hidradenitis suppurativa, a chronic inflammatory skin disease, and met its primary efficacy endpoints.

The result represents a step forward for Merck's pipeline in inflammatory conditions, though further studies will be needed to confirm the benefit.